ASH 2022 | Determinants of response to quadruplet therapy in multiple myeloma: genomic determinants & NK cells
Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, highlights findings from a study which investigated the immune microenvironment and markers present in tumors of patients with multiple myeloma to identify molecular variants which may predict outcomes to quadruplet treatment combination. Overall, the analysis found several genomic determinants of response to quadruplet treatment combination in patients with multiple myeloma as well as the advantageous impact NK cells have on treatment response. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
